NCT06964087
Pharmacokinetic and Early Efficacy of OPT101 in Patients With Type 1 Diabetes Mellitus
Recruiting
PHASE2Ages 18–50InterventionalTreatmentOp-T LLC
~72 participants
Updated 2026-04-06 on ClinicalTrials.gov
What's tested:OPT101OPT101 Placebo to Match (PTM)
At a glance
Recruiting sites
5 of 5 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in C-peptide (ng/mL)
Measured over 48-week
Conditions
Where it's being run
5 sites across 5 statesAlabama1
California1
Colorado1
Illinois1
Washington1
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
1\. Able and willing and able to give informed consent for the trial (separate consent must be obtained for Parts B or C).
Exclusion
1\. Current malignancy or history of malignancy other than basal cell carcinoma or squamous cell carcinoma in situ.
What this trial measures
- Change in C-peptide (ng/mL)48-week
Change from baseline to End of Study in mixed-meal stimulated C-peptide (ng/mL). The area under the time-C-Peptide curve (AUC) is calculated, and the weighted mean C-peptide is used to convert the measurement back to nanomoles per liter.